These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis. Bandyopadhyay S; Verma P; Samajdar SS; Das S Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102373. PubMed ID: 38719148 [TBL] [Abstract][Full Text] [Related]
11. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606 [TBL] [Abstract][Full Text] [Related]
12. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293 [TBL] [Abstract][Full Text] [Related]
13. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study. Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498 [TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703 [TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Fass R; Vaezi M; Sharma P; Yadlapati R; Hunt B; Harris T; Smith N; Leifke E; Armstrong D Aliment Pharmacol Ther; 2023 Nov; 58(10):1016-1027. PubMed ID: 37750406 [TBL] [Abstract][Full Text] [Related]
16. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Suzuki T; Kagami T; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T Eur J Clin Pharmacol; 2018 Jan; 74(1):45-52. PubMed ID: 28986609 [TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y Digestion; 2017; 95(4):281-287. PubMed ID: 28501868 [TBL] [Abstract][Full Text] [Related]
18. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms. Hoshikawa Y; Hoshino S; Kawami N; Iwakiri K J Gastroenterol; 2021 Feb; 56(2):117-124. PubMed ID: 33247348 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]